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Making Cancer History

Screening for
Cervical Cancer
Regular Pap smears
are still the key to
reducing mortality
rates.

4

Cervical Cancer
Clinical Trials
Protocols designed to
test the effectiveness
of cytotoxic agents
are included.

Stress and Cancer
The link between
stress and cancer is still
not clear, but there are
definite benefits to
reducing stress.

Reversing Treatment
Induced Sterility
Laboratory studies
of hormone inter
vention therapy
show promise.

J\ID Anderson
National Cooperation Leads to New
Standard of Treatment for Cervical Cancer
by Kerry L. Wright

n 1965, Drs. Felix
Rutledge, Gilbert
Fletcher, and Julian
Smith of The Univer
sity of Texas M. D.
Anderson Hospital and Tumor
Institute (now The University
of Texas M. D. Anderson
Cancer Center) combined
chemotherapy and radiation
therapy for the first time to treat
patients with cervical cancer.

Although their revolutionary
therapy did not become widely used
because there was no conclusive
scientific evidence to prove its benefit,
they left a legacy of cooperation
between the departments of Gyne
cologic Oncology and Radiation
Oncology. Now, 35 years later,
chemoradiation has become the
standard of treatment for patients
with locally advanced cervical cancer,
thanks to five national clinical trials
and the legacy of cooperation that
still remains.

Patricia Eifel, M.D., a professor in the Department of Radiation Oncology, and Mitchell
Morris, M.D., a professor in the Department of Gynecologic Oncology, were co-investiga
tors in a Radiation Therapy Oncology Group trial that helped bring about a change in
the standard treatment of patients with locally advanced cervical cancer.
The five chemoradiation trials were
conducted throughout the 1990's by
three National Cancer Institute (NCI)
Clinical Trials Cooperative Groups,
including the Radiation Therapy
Oncology Group (RTOG), which
worked with more than 20 institutions
led by M. D. Anderson. The RTOG
trial results, published last April in

The New England journal of Medicine,
showed that patients treated with
cisplatin, fluorouracil (5-FU), and
concurrent radiation had a 50%
higher five-year survival rate than
patients treated with radiation alone.
All five studies used cisplatinbased chemotherapy and low-dose
(Continued on next page)

New Standard of Treatment for Cervical Cancer
(Continued from page 1)

radiation, and all showed overall
survival rate increases between 30%
and 50 %, prompting a rare NCI
clinical alert last February.
"It really represented one of
the first times that we had powerful,
clear-cut evidence of a particular
treatment methodology being the
appropriate way to go," said Mitchell
Morris, M.D., professor in the Department of Gynecologic Oncology
at M. D. Anderson and co-principal
investigator of the RTOG trial.
Prior to release of the trial results,
radiation alone was the primary treatment for locally advanced cervical
cancer. Because its normal tissues
are highly radioresistant and because
radiation sources can be inserted
adjacent to it, the cervix is an ideal
target for this type of therapy.
"For many years, cervical cancereven some large cervical cancershas been treated successfully with
a combination of external-beam
radiation therapy and low-dose-rate
intracavitary radiation, where sources
are placed in the uterus and the
vagina, that can be delivered over
a couple of days," said Patricia Eifel,
M.D. , professor in the Department of
Radiation Oncology and co-principal
investigator, alongside Dr. Morris,
of the RTOG trial.
Radiation therapy has been successful in treating many types of cervical
cancer, and either radiation or surgery
alone remains the standard for treatment of small and localized tumors.
"The five-year survival rate for
patients with small cervical cancers,
less than 2 cm, who are treated
with radical surgery or radiation
is more than 90%," said
Charles Levenback, M.D.,
associate professor in the
Department of Gynecologic
Oncology.
Initially, neoadjuvant
chemotherapy (chemotherapy and radiation given
in sequence) was tested in
patients with larger and
more advanced tumors.
However, those studies
did not show a survival
advantage, possibly
2 / MD Anderson OncoLog

because in some cases the chemotherapy was ineffective and only
postponed radiation treatment,
said Dr. Levenback.
According to Dr. Eifel, radiation
treatment for cervical cancer was
already very specialized, and the
therapy is even more complicated now
that chemotherapy has been added.
In addition, there are only about
13,000 new cases of cervical cancer
a year in this country, making the
disease even more difficult to treat
for physicians in smaller institutions
who see only a few patients a year.
"To get the best results, I think this
is a disease that requires the patient
be treated in a place where there is
very close cooperation between
experienced gynecologic and radiation oncologists," Dr. Eifel said.
The chemoradiation regimen
currently used at M. D. Anderson
takes seven to eight weeks and
involves external radiation given five
times a week for four to five weeks,
followed by two 72-hour, intracavitary
treatments given two weeks apart.
Three cycles of chemotherapy are
delivered intermittently throughout
the entire period.
The radiation works by inducing
DNA damage to prevent cells from
replicating, and the simultaneous
chemotherapy enhances the effect.
"The cisplatin binds to the DNA
that is damaged by radiation, and
then the DNA is not easily repaired
anymore, and it enhances cell death,"
said Dr. Morris. "The other way it
works is on a systemic level," he said.
"One of the big issues remaining
is finding the most effective chemotherapy regimen with the fewest side

Regular Pap Smears
Still Key to Preventing
Cervical Cancer
by Kerry L. Wright

T

echnological advances have
improved methods of screening for cervical cancer, but
wh ether new devices or
traditional procedures are used,
the most important message remains:
all women should have a Pap smear
regularly.
According to Elise Cook, M.D.,
assistant professor in the Department
of Clinical Cancer Prevention at The
University of Texas M. D. Anderson
Cancer Center, collection, processing,
and evaluation of a Pap smear are
equally important in obtaining accurate results. She em phasizes that a
good collection will sample cells from
both the outside of the cervix (the
portio) and the inside, particularly the
squamocolumnar j unction, the area at
highest risk for developing cancer.

effects," said Dr. Levenback. Recent
discussions have focused on how
often drugs sh ould be delivered and
which of the d rug treatmentscisplatin and 5-FU togeth er, cisplatin
alone, or something e ntirely different-is the best. New compounds
such as oral flu oropyrimidines (oral
forms of 5-FU) are also being considered for testing to find new and
easier ways to administer the drugs.
While these new studies are being
designed, follow-up
studies from the initial
"One of the big issues
chemoradiation trials are
remaining is finding the
ongoing, and another
maj or analysis will probmost effedive chemotherapy ably be done in the next
regimen with the fewest
year, said Dr. Morris.
"We want to make sure
side effects."
that even though we see an
- Charles Levenback, M.D.,
improvement in survival,
associate professor in the Department
we're not j ust shifting the
of Gynecologic Oncology
survival curve [by increasing the long-term compli-

Recently, automated devices
d esigned to improve the processing
and evaluation of the test have
become available. While these
d evices are not routinely offered at
M. D. Anderson, they may be helpful
in settings where expert pathology
is not available.
"The concern about these new
Pap smear devices is that they
in crease cost, and we're not sure
th at we're getting much for our
in crease of cost," said Dr. Cook.
Many organizations and physicians,
in cluding Dr. Cook, feel that money
sh ould instead be spent on increasin g the number of women who are
screened. "That's where you'll get
th e decrease in cervical cancer,"
sh e said.
Unscreened populations often
in clude women who are not well
educated or who may have financial,
physical, or emotional barriers that
p revent them from having regular
screening. It is important to encourage these patients to have a Pap
sm ear, said Dr. Cook. Because rates

1

cations of the treatment] ," he said.
Though no major problems were
detected during the studies, radiation
injury and other complications may
take some time to surface.
Chemoradiation has significantly
changed the treatment of cervical
cancer, but exciting advances are also
being made in the area of tumor
vaccines. The highest risk factor for
developing cancer of the cervix is
infection with specific strains of the
human papillomavirus (HPV), and
both prophylactic vaccines that would
be administered to everyone before
they could contract the virus and
treatment vaccines that might be of use
after infection are being developed.
"HPV vaccines, especially those
that produce antibodies to the late
envelope proteins, may be important
for reducing oncogenic viruses. This
could lead to a reduction in cervical
cancer over the long term," said
Ralph Freedman, M.D., Ph.D. ,

Cervical Cancer
Screening
Recommendations
According to the "American Cancer
Society Recommendations for
the Early Detection of Cancer in
Average Risk, Asymptomatic
People;' all women who are or have
been sexually active or have reached
age 18 should have an annual Pap
test and pelvic examination. After a
woman has had 3 or more consecutive satisfactory normal annual
examinations, the Pap test may be
performed less frequently at the
discretion of the physician.

of cervical cancer increase with age,
older women who have never had a
Pap smear should especially be
encouraged to have one.
Once these populations have

professor in the Department of
Gynecologic Oncology.
M. D. Anderson is one of four
institutions participating in an
international study of a vaccine
developed to treat patients with both
preinvasive and invasive cervical
cancer. In collaboration with Raymond
Kaufman, M.D., professor in the
Department of Obstetrics and Gynecology at Baylor College of Medicine,
Dr. Freedman is evaluating responses
at the laboratory level of patients
treated at Baylor with the novel
treatment vaccine.
Like the influenza virus, there
are many strains of HPV, and the
number is constantly increasing.
Only a few strains are associated
with cervical cancer, so these are
the ones that must be tracked and
targeted for the vaccines.
"There has been a lot of progress
made, and some of the early reports
of human trials are showing that the

been screened, it is also important
for the patients to receive further
care if their test results are abnormal.
Michele Follen, M.D., professor in
the Department of Gynecologic
Oncology at M. D. Anderson, holds
a weekly clinic at Lyndon B. Johnson
General Hospital in Houston for
underprivileged patients who have
had abnormal Pap smears. These
patients undergo colposcopies and
other biopsies to further detect and
identify abnormalities.
Since the development of the Pap
smear by George Papanicolaou in 1941,
U.S. cervical cancer mortality rates have
decreased more than 70%. However,
about 13,000 American women still
develop cervical cancer each year, and
5,000 still die from the disease.
Dr. Cook said that to help prevent
these cases, physicians should offer
their patients advice from the following list: "Numbers 1, 2, 3, and 4 are
'get a Pap smear,"' she said. •
FOR MORE INFORMATION,

contact Dr. Cook

at (713) 745-8048.

vaccines are having a good response,"
said Dr. Morris.
Only one generation removed
from the fathers of chemoradiation
and heading into a new millennium,
laboratory scientists and physicians
are working together to one day
eliminate-or at least hold the power
to eliminate-cervical cancer.
"I think there's a good chance
that an HPV vaccine that effectively
prevents infection will be in use
sometime in the next decade, and
then you could eradicate cervical
cancer," said Dr. Morris. "It would
be amazing." •
contact Dr. Morris
at (713) 745-3000, Dr. Eifel at (713) 7923444, Dr. Levenback at (713) 745-2563,
or Dr. Freedman at (713) 792-2764.

FoR MORE INFORMATION,

Turn to page 4 for Cervical
Cancer Protocols.
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Cervical Cancer
Clinical Trials
Clinical trials in progress at The University of Texas M. 0. Anderson Cancer Center
include the following for patients with
cancer of the cervix.
• A limited-access phase II trial of
cisplatin and vinorelbine (navelbine) in
advanced and recurrent squamous cell
carcinoma of the cervix (GOG 76-Z).
Physician: Mitchell Morris, M.D.
This study is designed for patients
with histologically confirmed advanced,
persistent, or recurrent squamous
cell carcinoma of the cervix who have
documented disease progression after
local therapy. Participants must have
measurable disease that can be defined
in two dimensions by palpation , x-ray,
or ultrasonography. If a patient's only
measurable site of disease has been
irradiated previously, disease progression at the site must be documented
before enrollment in this study.
• A randomized , double-blind study of
eflornithine (OFMO) versus placebo in
patients with grade 2 or 3 cervical
intraepithelial neoplasia (CIN) (1092026). Physician: Michele Fol/en, M.D.
This study is designed for women
age 18 or older with newly diagnosed
or recurrent grade 2 or 3 CIN lesions
that are two to three times larger than
the biopsy site. Participants must have
a life expectancy of at least 12 months
and use adequate contraception during
the study. Patients who have had a
prior malignancy are not eligible.
• Phase 1/11 study of farnesyl transferase
inhibitor (SCH 66336) in combination
with paclitaxel in solid tumors (1098369). Physician: Fad/a R. Khuri, M.D.
Study participants are patients with
histologically confirmed solid tumors
for wh ich no treatment that would have
a reasonable chance of disease palliation
or cure is available. Participants must
have measurable disease and no
manifestations of malabsorption
syndrome. Patients who have received
more than two prior chemotherapy
regimens, prior wide-field radiation
therapy, or prior allogeneic, syngeneic,
or autologous bone marrow transplanta4 I MD Anderson OncoLog

PROTOCOLS --+-~- - -

tion or stem cell transplantation are not
eligible. Patients who are poor medical
risks because of nonmalignant systemic
disease or an active infection and
patients with a medical condition that
prevents them from taking oral medications may not participate.
• Phase I study of 9-nitro-20(S)camptothecin (rubitecan) in combination
with cisplatin in patients with advanced
malignancies (1099-166). Physician:
Claire F Verschraegen, M.D.
Patients 1Oyears old or older with
recurrent or refractory cancers in a
variety of sites, including the cervix, in
which standard chemotherapy regimens
have failed are eligible for this study.
Patients with symptomatic brain metastases, pregnant women or nursing
mothers, and those receiving other
concurrent chemotherapy or radiation
therapy are not eligible. Patients of
childbearing potential must use adequate
contraception.
• A phase II study of intravenous OX8951 f administered daily for five days
every three weeks to patients with
advanced or recurrent squamous cell
cancer of the cervix (OM99-247).
Physician: Andrzej Kudelka, M.D.
Women age 18 and older with
advanced or recurrent histologically
confirmed squamous cell carcinoma
of the cervix deemed not curable by
surgery or radiation therapy are eligible.
Patients may have undergone up to one
prior chemotherapy regimen , and at
least four weeks must have elapsed
since any prior surgery, radiation
therapy, or chemotherapy. Participants
must have measurable disease and
no concurrent serious infection.
• A randomized , double-blind study of N(4-hydroxyphenyl) retinamide (4-HPR)
(fenretinide) versus placebo in patients
with grade 2 or 3 cervical intraepithelial
neoplasia (CIN) (1092-027). Physician:
Michele Fol/en, M.D.
This study is open to women age 18
years and older with a newly diagnosed
or recurrent GIN grade 2 or 3 lesion
involving at least one quadrant of the
transformation zone of the cervix.
Patients must have a life expectancy
of at least 12 months and cannot have
had any prior malignancies. An ap-

proved form of contraception must be
used for the duration of the study.
• Feasibility of co mbined intraoperative
lymphatic mapping and sentinel node
identification in patients with cervical
cancer (1099-131 ). Physician: Charles
F Levenback, M.D.
This pilot study is designed for
patients with invasive cervical cancer
who are undergo ing surgical assessment of pelvic and/or para-aortic lymph
nodes. Follow-up depends on the
outcome of the surgery, but routine
follow-up for low-risk patients is a clinic
visit every th ree to six months for five
years. Patients with known allergies to
triphenylmethane com pou nds are not
eligible for this study.
• A phase II trial of Taxol (paclitaxel) in
patients with advanced adenocarcinoma
of the uterine cervix (GYN93-009).
Physician: Mitchell Morris, M.D.
Participants must have microscopically
confirmed advanced adenocarcinoma of
the cervix that is not considered curable
by surgery or radiation therapy. Patients
must have bidimensionally measurable
disease with histologic slides and/or
blocks available for review. Patients
may have received chemotherapy as
a radiosensitizer in conjunction with
radiation therapy but cannot have
received chemotherapy alone for
recurrent or metastatic disease.
• A pilot study to measu re optical coherence tomography images of cervical
intraepithelial neoplasia (GIN) (GYN98047). Physician: Michele Fol/en, M.D.
Study participants will undergo a
one-time measurement of the cervix.
Participants must be older than 18 and
must be referred to the M. 0. Anderson
Colposcopy Cli nic. Pregnant patients
are not eligible. •
about these clinical
trials, p hysicians or patients may call the
M . D. Anderson Information Line. Those
within the United States should call ( 800)
3 92-1611; those in Houston or outside
the United States shou ld call (713) 7926161. Visit the M. D. Anderson Cancer
Center clinical trials web site at http://
www.clinicaltrials.org for a broader
listing of treatment research protocols.
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Stress and Cancer: What's the Connedion?
n unavoidable fact of modern life, stress has been
linked to disorders rangi,ng from headaches to heart
disease. But does stress cause cancer? The results of
recent research studies show no direct cause-and-effect
relationship between stress and an individuals risk of
developing cancer, but there may be a link between stress
and disease response to cancer therapy.

What does the research tell
us about stress and cancer?
Research has shown that stressful
life situations such as social isolation
or the death of a spouse alter the
function of the body's immune system,
our defense against infection and
disease. But this research has provided
no scientific evidence that these stressinduced changes in the immune system
directly cause cancer, according to the
National Cancer Institute.
One study of 332 women, reported
in the British Medical Journal, found
that women in a group who were
diagnosed with breast cancer were
no more likely than h ealthy women
to have experienced a severe life
event during the previous five years.
However, the study only takes into
account life events and does not
measure stress, which is a person's
psychological and physiological
response to those events. Some
research suggests there is a link
between psychological status and
the development and progression
of cancer, but to determine the true
association between stress and the
development of cancer, more studies
are needed.
Other research has examined
the effect of stress on patients already
diagnosed with cancer. A stud~ published in the journal of the National
Cancer Institute evaluated the anxiety
of 116 women who had surgery for
breast cancer. The researchers found
that the patients with the most anxiety
about their medical conditions had
the lowest levels of white blood cells,
which are critical to immune function,

and that the white blood cells that
remained functioned at lower than
normal levels.

Can patients with cancer
benefit from reduced stress?
Being diagnosed with cancer
can, of course, be extremely stressful.
However, patients who have a good
attitude and good coping skills tend
to have more successful cancer
treatment, possibly because these
patients find and then comply with
the most effective treatment available.
Scientists are now studying whether
stress reduction can improve a cancer
patient's prognosis. Several studies
seem to indicate that social support
groups may enhance survival for
cancer patients. These support groups
allow patients to share their concerns
with other cancer patients and to
learn new ways to handle problems.
Other techniques that have been
used to help reduce cancer patients'
stress include meditation, progressive
muscle relaxation, visual imagery,
visualizations, and various forms of
psychotherapy.

How can we manage stress
in our daily lives?
Stress management is an important skill for all of us to master. But
how can we change the way we react
to stressful modern life? Experts
advise that a first step is becoming
aware of our own individual stress
symptoms. Do you, for instance, get
headaches whenever you're stuck
in traffic? Identifying the specific

triggering situations and our responses
can help us manage that stress in
better ways.
Stress originates from three general
sources: the environment, our bodies,
and our thoughts. Although we may
have some control over our environmen ts and bodies, we have much
more control over the way we think
about a stressful situation.
A large part of stress management,
according to stress researchers,
involves changing our appraisal so
that a difficult situation is seen as a
challenge instead of a threat.
It is also helpful to identify our
thoughts or internal dialogues that
are negative, perfectionistic, or rigid.
We can challenge these thoughts,
asking, for instance, "Why must I do
this perfectly?" Then we can begin to
replace the negative internal dialogue
with more productive thoughts.
We can also minimize stress by
exercising, eating a balanced diet,
getting enough rest, and making
time for pleasurable leisure activities.
There is a great deal that all of us can
do to help manage the inevitable
stress that comes into our lives. •
For more information, contact
your physician or contact the
M. D. Anderson Information Line:

({) (800) 392-1611 within
the United States, or
({) (713) 792-6161 in Houston
and outside the United States.
February 2000
© 2000 The University of Texas
M. D. Anderson Cancer Center

Researchers Study Hormone
Intervention Therapy to Prevent
Treatment-Induced Sterility
by Mariann Crapanzano

o help young cancer
survivors fully live
the life that awaits
them-a life that,
for many, includes having
children and raising a familyresearchers at The University of
Texas M. D. Anderson Cancer
Center are exploring the use of
hormone interventions to protect fertility from the effects of
chemotherapy and radiation
therapy. Marvin L. Meistrich,
Ph.D., a professor in the Department of Experimental
Radiation Oncology, is studying the causes and prevention
of chemotherapy-induced and
radiation-induced sterility in
male laboratory animals.

T

Conventional doses of radiation
and many of the chemotherapeutic
agents used to treat diseases such as
Hodgkin's disease, lymphoma, bone
and soft tissue sarcomas, testicular
cancer, and leukemia often impair
the production of sperm for prolonged periods. And while the testes
may sometimes be shielded from
direct radiation (as in the case of
some patients with Hodgkin's disease), they cannot be completely
shielded from scattered radiation and
are exposed to systemically administered chemotherapeutic drugs.
Dr. Meistrich said that Hodgkin's
disease brought the problem of

Studies led by Marvin L. Meistrich, Ph.D.,
a professor in the Department of Experimental Radiation Oncology, are investigating the effectiveness of hormone
manipulation in restoring mal,e fertility
after chemotherapy or radiation therapy.
6 / MD Anderson OncoLog

infertility to the forefront because
it is frequently diagnosed in young
patients and was for many years-and,
in rare cases of advanced or recurrent
disease, still is-effectively treated
using chemotherapy related to the
highly sterilizing MOPP (mechlorethamine, vincristine, procarbazine,
and prednisone) regimen.
Dr. Meistrich believes understanding the mechanisms by which chemotherapy and radiation therapy affect
the testes is key to restoring spermatogenesis after cancer treatment. The
human testes have a finite number
of stem spermatogonia cells-those
cells that replicate themselves and
differentiate into spermatocytes,
which develop into mature sperm.
Other cells within the testes support
the maturation of sperm. Alkylating
agents (including procarbazine,
cyclophosphamide, busulfan, and
chlorambucil), platinum drugs
(including cisplatin), and radiation
beyond certain doses have been
shown to impede this process of
spermatogenesis.
According to Dr. Meistrich, the
results of early studies led researchers
to believe that certain doses of some

chemotherapeutic agents and radiation killed all stem cells, resulting in
permanent azoospermia (the absence
of sperm in the semen). Now researchers are questioning this hypothesis.
Histologic sections of the testes of
laboratory rats that failed to produce
sperm for a year after being irradiated
showed that stem cells were present
but were not maturing normally.
The same may be true in humans.
"We've seen several patients who
were azoospermic for years and then,
apparently spontaneously, recovered
sperm production and fertility," said
Dr. Meistrich.
Fredrick B. Hagemeister, M.D.,
a professor in the Department of
Lymphoma and Myeloma at M. D .
Anderson, also said that many
patients with cancer who survive
at least seven to eight years after
therapy recover spermatogenesis
within that time. This evidence
suggests that after cancer treatment,
stem cells may be present in the
testes but are dormant. The challenge is to discover a way to jumpstart those cells.

Testosterone (produced in the
testes and normally found in high
concentrations there) and folliclestimulating hormone (FSH) (produced in the pituitary gland) are
both necessary for spermatogenesis.
Dr. Meistrich said that following
treatment with some chemotherapeutic agents or radiation, however,
spermatogenesis seems to be inhibited by testosterone. "The hormone
that is supposed to help spermatogenesis to go to completion now [after
chemotherapy or radiation therapy]
actually inhibits the first step," said
Dr. Meistrich.
Dr. Meistrich suppressed intratesticular testosterone levels in
laboratory rats by administering a
gonadotropin-releasing hormone
(GnRH) agonist for 10 weeks immediately following treatment of the
animals with chemotherapy or radiation therapy. The GnRH agonist
treatment overcame the inhibitory
effects of the cancer treatment, and
spermatogenesis increased. Even after
GnRH agonist administration was
stopped, the rats continued to produce sperm. Furthermore, Dr.
Meistrich's research showed that
recovery of spermatogenesis and
restoration of fertility was possible
when the GnRH agonist treatment
was initiated five months after irradiation, but the degree of recovery was
less than when the treatment was
initiated sooner.
The effect of GnRH agonist in
female animals is less clear. In one
study of female rats, GnRH agonist
given along with cyclophosphamide
enhanced the number of developing
ovarian follicles several months after
treatment. But Dr. Meistrich said the
GnRH agonist may have prolonged
fertility by inhibiting the normal
loss of follicles over an appreciable
fraction of the animal 's reproductive
lifetime. If so, the same treatment in
women-whose reproductive lifespan
is much longer-may not have a
significant impact.
Dr. Meistrich's research has shown
that suppression of testosterone and
FSH does not protect the stem cells
from the effects of chemotherapy
and radiation therapy (some stem
cells still die), but the hormone
manipulation does allow the remain-

ing living cells to differentiate and
complete the development to mature
spermatozoa.
If the mechanisms that mediate
the disruption and potential recovery
of spermatogenesis after chemotherapy or radiation therapy are
similar in humans and laboratory
animals, this hormone manipulation
therapy may hold hope for restoring
the fertility of young male cancer
survivors who do not spontaneously
recover spermatogenesis after cancer
treatment.
Testicular cancer and its treatment present additional challenges
to preserving fertility. Robert J.
Amato, M.D., associate professor in
the Department of Genitourinary
Medical Oncology, said that the
chemotherapeutic drugs used to
treat testicular cancer cause infertility
in approximately one fourth of
patients. The disease itself also
frequently adversely affects sperm
production, according to Christopher G. Wood, M.D., an assistant
professor in the Department of
Urology. In addition, some patients
undergo a retroperitoneal lymph
node dissection, which impairs their
ability to ejaculate semen. Dr. Wood
said that in such cases viable sperm
produced in the testis that is not
surgically removed can be retrieved
using methods such as electroejaculation and epididymal aspiration. "If there are viable sperm," Dr.
Wood said, "they can be reached."
Therefore, by restoring spermatogenesis, hormone interventions may
even benefit patients with testicular
cancer whose ejaculatory function is
impaired.
For now, however, Drs. Amato,
Wood, and Hagemeister recommend
semen cryopreservation (sperm
banking) to their patients who want
to have children after cancer treatment. "I recommend sperm banking
for all of my patients with testicular
cancer," Dr. Amato said.
Dr. Meistrich said that because
genetic alterations can occur in
sperm that are produced during
chemotherapy or radiation therapy,
it is important to collect the semen
samples for cryopreservation before
treatment begins. Because diagnosis
and the commencement of treatment

often occur within a very short time
frame, Dr. Meistrich urges physicians
who suspect that one of their male
patients has a cancer that might be
treated with radiation or chemotherapy to immediately discuss with
the patient the risk of sterility and
the option of sperm banking.
This applies even to cases in which
the patient is scheduled to undergo
a chemotherapy regimen that may
not be permanently sterilizing. The
reason: the patient may not respond
to the initial treatment or may have
a relapse and require stronger, more
sterilizing agents to treat the disease.
At that time, however, collecting an
adequate amount of sperm for cryopreservation may not be possible
because the patient's sperm count
may still be depressed or absent
from the initial treatment.
Cryopreservation of a woman's
oocytes is still an experimental
procedure. Offspring have been born
using frozen human oocytes in in vitro
fertilization procedures, but the
success rate is very low. Also under
investigation is cryopreservation of
ovarian tissue slices, a technique
that has restored ovarian endocrine
function and fertility in sheep. Restoration of hormone production and
follicular growth following transplantation of cryopreserved ovarian tissue
has been reported, but the long-term
success of the technique has not been
determined. Similarly, clinical trials
of GnRH agonist in women with
Hodgkin's disease have not yielded
conclusive results.
While there are no solid leads in
the search for effective methods of
preserving fertility in women with
cancer, Dr. Meistrich hopes that
hormone intervention therapy in
men will one day provide an alternative to the use of cryopreserved
semen. If clinical trials are undertaken
and confirm the results obtained in
Dr. Meistrich's studies at M. D. Anderson, the futures of more young cancer
survivors may include having children
and raising a family. •
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FOR MORE INFORMATION, contact Dr.
Meistrich at (713) 792-3424, Dr. Amato

at (713) 792-2830, Dr. Wood at (713)
792-3250, or Dr. Hagemeister at (713)
745-4245.
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